| Literature DB >> 35140585 |
Qiang Zhu1, Yuchao Liang1, Ziwen Fan1, Yukun Liu1, Chunyao Zhou1, Hong Zhang1, Tianshi Li1, Yanpeng Zhou1, Jianing Yang1, Yinyan Wang1, Lei Wang1.
Abstract
OBJECTIVE: Ischemic infarction of pituitary apoplexy (PA) is a rare type of pituitary apoplexy. This study aims to characterize ischemic PA via clinical presentations, imaging data, histopathological manifestations, and focus on the management and prognosis of the disease.Entities:
Keywords: coagulative necrosis; ghost cells; ischemic infarction; pituitary apoplexy; pituitary ring sign
Year: 2022 PMID: 35140585 PMCID: PMC8818988 DOI: 10.3389/fnins.2021.808111
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
Baseline characteristics of among 46 patients with ischemic PA.
| Clinical factors | Values |
| Age (yr) | 46.78 ± 12.32 |
| Sex (M/F) | 35M/11F |
|
| |
| Headache | 95.65% (44/46) |
| Nausea and vomiting | 58.70% (27/46) |
| Hyponatremia | 39.13% (18/46) |
| Diabetes insipidus | 10.87% (5/46) |
| Fever | 10.87% (5/46) |
|
| |
| Decrease visual acuity | 89.13% (41/46) |
| Visual field deficit | 82.61% (38/46) |
| Ocular palsy | 50.00% (23/46) |
|
| |
| Hypocorticolism | 52.17% (24/46) |
| Hypothyroidism | 36.96% (17/46) |
| Hypogonadism | 84.78% (39/46) |
| Corticotropic deficiency or secondary hypothyroidism | 58.70% (27/46) |
| Corticotropic deficiency and secondary hypothyroidism | 30.43% (14/46) |
|
| |
| Maximal tumor diameter (mm) | 26.54 ± 6.03 |
| Knosp classification (1–2 vs. 3–4) | 28 vs. 14 |
| Pituitary ring sign | 85.37% (35/41) |
| Thickening of the sphenoid sinus mucosa | 56.52% (26/46) |
| Ischemic imaging | 23.91% (11/46) |
|
| |
| Surgery (early vs. delayed) | 12 vs. 33 |
| EOR (Total resection vs. Subtotal resection) | 27 vs. 19 |
|
| |
| NFPA vs. FPA | 36 vs. 6 |
|
| |
| Duration (m) | 66.29 ± 32.85 |
| Recurrence | 2 |
NFPA, non-functioning pituitary apoplexy; FPA, functioning pituitary apoplexy; yr, year; M, male; F, female; mm, millimeter; m, month; EOR, extent of resection.
Comparison of clinical presentation and outcomes of ischemic PA between early and delayed surgery groups.
| Early surgery ( | Delayed surgery ( | ||
| Age | 46.58 ± 14.34 | 46.30 ± 11.65 | 0.864 |
| Sex | 11M/1F | 24M/9F | 0.344 |
|
| |||
| Headache | 100% (12/12) | 96.97% (32/33) | 1 |
| Nausea and vomiting | 66.67% (8/12) | 57.58% (19/33) | 0.836 |
| Hyponatremia | 50.00% (6/12) | 63.64% (21/33) | 0.409 |
|
| |||
| Decrease visual acuity | 91.67%% (11/12) | 90.91% (30/33) | 1 |
| Visual field deficit | 83.33% (10/12) | 51.52% (17/33) | 0.114 |
| Ocular palsy | 41.67% (5/12) | 54.55% (18/33) | 0.445 |
|
| |||
| Hypocorticolism | 50.00% (6/12) | 54.55% (18/33) | 0.787 |
| Hypothyroidism | 16.67% (2/12) | 45.45% (15/33) | 0.157 |
| Hypogonadism | 83.33% (10/12) | 84.85% (28/33) | 1 |
| Corticotropic deficiency or secondary hypothyroidism | 50.00% (6/12) | 63.64% (21/33) | 0.409 |
| Corticotropic deficiency and secondary hypothyroidism | 16.67% (2/12) | 36.36% (12/33) | 0.369 |
|
| |||
| Maximal tumor diameter | 27.08 ± 5.089 | 25.70 ± 5.193 | 0.430 |
| Knosp classification | (5 vs. 6) | (7 vs. 24) | 0.049 |
| Pituitary ring sign | 100% (11/11) | 79.31% (23/29) | 0.162 |
| Thickening of sphenoid sinus mucosa | 83.33% (10/12) | 53.33% (16/33) | 0.080 |
|
| |||
| Total improved vision | 90.91% (10/11) | 82.14% (23/28) | 0.850 |
| Total improved ocular palsy | 100% (5/5) | 100% (16/16) | – |
| Improved hypocortisolism | 20% (1/5) | 13.33% (2/15) | – |
| Improved hypothyroidism | 0% (0/2) | 35.71% (5/14) | – |
| EOR | 1 vs. 11 | 19 vs. 14 | 0.009 |
| Follow-up (m) | 72.11 ± 28.52 | 64.51 ± 34.90 | 0.504 |
*P-value calculated by t-test.
Comparison of clinical presentation and outcomes of ischemic PA between NFPA and FPA groups.
| Clinical factors | NFPA ( | FPA ( | |
| Age | 47.56 ± 12.25 | 36.33 ± 8.45 | 0.038 |
| Sex (M/F) | 29M/7F | 4M/2F | 0.593 |
|
| |||
| Headache | 97.22% (35/36) | 83.33% (5/6) | 0.268 |
| Nausea and vomiting | 58.33% (21/36) | 28.57% (2/6) | 0.384 |
|
| |||
| Decrease visual acuity | 97.22% (35/36) | 66.67% (4/6) | 0.049 |
| Visual field deficit | 66.67% (24/36) | 50.00% (3/6) | 0.649 |
| Ocular palsy | 50.00% (18/36) | 16.67% (1/6) | 0.282 |
|
| |||
| Hypocortisolism | 52.78% (19/36) | 33.33 (2/6) | 0.663 |
| Hypothyroidism | 41.67% (15/36) | 16.67% (1/6) | 0.476 |
| Hypogonadism | 80.56% (29/36) | 100% (6/6) | 0.567 |
| Corticotropic deficiency or secondary hypothyroidism | 58.33% (21/36) | 33.33% (2/6) | 0.384 |
| Corticotropic deficiency and secondary hypothyroidism | 33.33% (12/36) | 16.67% (1/6) | 0.733 |
|
| |||
| Maximal tumor diameter | 26.25 ± 5.26 | 27.67 ± 10.33 | 0.603 |
| Knosp classification | 81.25% (26/32) | 100% (6/6) | 0.562 |
| Pituitary ring sign | 63.33% (19/30) | 85.71% (6/7) | 0.389 |
| Thickening of sphenoid sinus mucosa | 57.58% (20/36) | 71.43% (4/6) | 0.685 |
| Ischemic imaging | 34.62% (9/36) | 14.29% (1/6) | 1 |
|
| |||
| Surgery (early vs. delayed) | 32.35% (11/36) | 16.67% (1/5) | 1 |
|
| |||
| Total improved vision | 84.85% (28/33) | 100% (4/4) | 1 |
| Total improved ocular palsy | 100% (18/18) | 100% (1/1) | – |
| Improved hypocortisolism | 6.25% (1/16) | 0% (0/1) | – |
| Improved hypothyroidism | 23.08% (3/13) | 0% (0/1) | |
| EOR | 14:22 | 4:2 | 0.375 |
| Follow-up | 68.43 ± 31.57 | 79.32 ± 33.36 | 0.442 |
*P-value calculated by t-test.
FIGURE 1The MRI showed iso-intensity in T1-weighted imaging (A, sagittal) and hyperintensity in T2-weighted imaging (B, axial). After gadolinium administration, the imaging showed central iso-intensity with an enhanced rim (C, coronal). Histological manifestation (D) showed a large area of red massive coagulative necrosis without cellular structure (H&E ×100).
Baseline characteristics of patients with ischemic PA between preoperative and postoperative.
| Preoperative | Postoperative | |
|
| ||
| Headache | 95.65% (44/46) | 0 |
| Hyponatremia | 36.96% (17/46) | 0 |
| Diabetes insipidus | 10.87% (5/46) | 0 |
|
| ||
| Decrease visual acuity | 89.13% (41/46) | 15.91% (7/44) |
| Visual field deficit | 60.87% (28/46) | 11.11% (3/27) |
| Ocular palsy | 50.00% (23/46) | 0 |
|
| ||
| Hypocortisolism | 52.17% (24/46) | 65.00% (26/40) |
| Hypothyroidism | 36.96% (17/46) | 46.34% (19/41) |
| Hypogonadism | 82.61% (38/46) | 63.16% (24/38) |